Ultime notizie per Prothena Corp (NASDAQ:PRTA) Azioni

Prothena Corp

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Prothena Corporation plc - Ordinary Shares

Prothena Corp PLC

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $50.25, a high estimate of $84.00, and a low estimate of $24.00. A 4.74% drop is evident in the current average compared to the previous average price target of $52.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1727787662_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Prothena Corp by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Prothena Corp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Prothena Corp's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Prothena Corp's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Prothena Corp: A Closer Look</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>A Deep Dive into Prothena Corp's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Prothena Corp showcased positive performance, achieving a revenue growth rate of 3184.75% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Prothena Corp's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 50.67% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Prothena Corp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.34% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Prothena Corp's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.54% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Prothena Corp's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

PRTA

Breaking Down Prothena Corp: 4 Analysts Share Their Views

B of A Securities analyst Tazeen Ahmad maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Neutral and lowers the price target from $33 to $31.

News

Price Target

B of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $31

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and maintains $84 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $84 Price Target

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 300 points during on Monday.
The Dow traded down 0.71% to 42,012.42 while the NASDAQ fell 0.52% to 18,026.03. The S&amp;P 500 also fell, dropping, 0.45% to 5,712.53.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/41091653/how-to-earn-500-a-month-from-mccormick-stock-ahead-of-q3-earnings">How To Earn $500 A Month From McCormick Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Communication services shares fell by just 0.1% on Monday.
In trading on Monday, materials shares dipped by 1.3%.
Top Headline
Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) posted better-than-expected quarterly earnings.
Carnival posted adjusted earnings of $1.27 per share, beating analysts' estimates of $1.16 per share. The company posted quarterly sales of $7.90 billion versus expectations of $7.83 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>ZEEKR Intelligent Technology Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) shares shot up 9% to $22.95. Shares of US-listed Chinese companies traded higher on continued strength amid stimulus efforts. September PMI data beat estimates but factory activity fell, which may raise stimulus hopes.</li>
<li>Shares of Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) got a boost, surging 13% to $3.9140 after the company announced a strategic research collaboration and license agreement with Bristol Myers Squibb to develop reagents for the next generation of ex vivo T-cell therapies. Also, it announced that it is focusing its pipeline on a set of high value programs.</li>
<li>EMCORE Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMKR#NASDAQ">EMKR</a>) shares were also up, gaining 74% to $2.10 after Mobix Labs submitted an all-cash offer to acquire the company for $3.80 per share.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares dropped 15% to $17.01. Prothena announced leadership team updates. Cantor Fitzgerald analyst Charles Duncan reiterated Prothena with an Overweight rating.</li>
<li>Shares of Heritage Insurance Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NASDAQ">HRTG</a>) were down 20% to $12.44.</li>
<li>Stellantis N.V. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) was down, falling 13% to $13.91 after the company lowered its FY24 guidance.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $68.12 while gold traded down 0.4% at $2,656.90.
Silver traded down 1.5% to $31.33 on Monday, while copper fell 1.1% to $4.5490.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.98%, Germany's DAX fell 0.76% and France's CAC 40 dipped 2.00%. Spain's IBEX 35 Index fell 0.76%, while London's FTSE 100 fell 1.01%.
The British economy grew by 0.5% on quarter during the second quarter, down from 0.7% in the first quarter, while the UK's current account deficit widened to £28.4 billion in the second quarter, versus a revised £13.8 billion in the prior quarter. Net consumer credit in the U.K. rose by £1.3 billion in August, from £1.2 billion in the previous month. German import prices increased by 0.2% year-over-year in August compared to a 0.9% rise in July.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 dipping 4.80%, Hong Kong's Hang Seng Index jumping 2.43%, China's Shanghai Composite Index gaining 8.06% and India's BSE Sensex falling 1.49%.
Japan&#8217;s housing starts fell by 5.1% year-over-year in August compared to a 0.2% decline in the prior month, while industrial production fell by 3.3% month-over-month in August. Retail sales in Japan climbed by 2.8% year-over-year in August.
The official NBS Non-Manufacturing PMI in China fell to 50.0 in September from 50.3 in the prior month, while official NBS Manufacturing PMI climbed to 49.8 in September from 49.1 in August.
Economics
The Chicago PMI rose to 46.6 in September from 46.1 in August versus market estimates of 46.2.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41064318/top-3-real-estate-stocks-that-are-preparing-to-pump-this-month">Top 3 Real Estate Stocks That Are Preparing To Pump This Month</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

EMKR

HRTG

PRME

STLA

Dow Dips 300 Points; Emcore Shares Spike Higher

<h3>Gainers</h3>
<ul>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock moved upwards by 38.8% to $13.82 during Monday's regular session. The company's market cap stands at $488.1 million. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) shares moved upwards by 36.58% to $0.74. The company's market cap stands at $54.2 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock moved upwards by 32.73% to $0.47. The company's market cap stands at $35.5 million. </li>
<li>Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) stock rose 27.82% to $4.87. The company's market cap stands at $7.5 million. </li>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock increased by 16.44% to $4.03. The company's market cap stands at $483.5 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock moved upwards by 16.35% to $0.59. The market value of their outstanding shares is at $22.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock decreased by 28.8% to $0.46 during Monday's regular session. The company's market cap stands at $6.0 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares declined by 27.4% to $0.67. The company's market cap stands at $6.9 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock decreased by 25.87% to $0.36. The company's market cap stands at $2.6 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares decreased by 20.04% to $1.48. The company's market cap stands at $8.7 million. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares fell 19.87% to $16.07. The market value of their outstanding shares is at $864.0 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 18.81% to $0.36. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APDN

BNOX

CAPR

ALPS ETF Trusthen & Steers Global Realty Majors ETF

HCWB

PSTV

XBIO

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points during on Monday.
The Dow traded down 0.55% to 42,079.06 while the NASDAQ rose 0.14% to 18,144.66. The S&amp;P 500 also fell, dropping, 0.14% to 5,730.18.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/41091653/how-to-earn-500-a-month-from-mccormick-stock-ahead-of-q3-earnings">How To Earn $500 A Month From McCormick Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Consumer staples shares jumped by 0.3% on Monday.
In trading on Monday, materials shares fell by 0.6%.
Top Headline
The Chicago PMI rose to 46.6 in September from 46.1 in August versus market estimates of 46.2
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares shot up 11% to $7.24 after investors agreed to invest an aggregate of 3.3 billion yuan in its Nio China subsidiary while the company agreed to invest 10 billion yuan.</li>
<li>Shares of Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) got a boost, surging 23% to $4.26 after the company announced a strategic research collaboration and license agreement with Bristol Myers Squibb to develop reagents for the next generation of ex vivo T-cell therapies. Also, it announced that it is focusing its pipeline on a set of high value programs.</li>
<li>EMCORE Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMKR#NASDAQ">EMKR</a>) shares were also up, gaining 71% to $2.06 after Mobix Labs submitted an all-cash offer to acquire the company for $3.80 per share.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares dropped 19% to $16.31. Prothena announced leadership team updates. Cantor Fitzgerald analyst Charles Duncan reiterated Prothena with an Overweight rating.</li>
<li>Shares of Heritage Insurance Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NASDAQ">HRTG</a>) were down 17% to $12.94.</li>
<li>Stellantis N.V. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) was down, falling 14% to $13.79 after the company lowered its FY24 guidance.</li>
</ul>
Commodities In commodity news, oil traded up 0.9% to $68.81 while gold traded down 0.5% at $2,655.10.
Silver traded down 1.2% to $31.44 on Monday, while copper fell 1.4% to $4.5340.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.84%, Germany's DAX fell 0.66% and France's CAC 40 dipped 1.71%. Spain's IBEX 35 Index fell 0.52%, while London's FTSE 100 fell 0.81%.
The British economy grew by 0.5% on quarter during the second quarter, down from 0.7% in the first quarter, while the UK's current account deficit widened to £28.4 billion in the second quarter, versus a revised £13.8 billion in the prior quarter. Net consumer credit in the U.K. rose by £1.3 billion in August, from £1.2 billion in the previous month. German import prices increased by 0.2% year-over-year in August compared to a 0.9% rise in July.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 dipping 4.80%, Hong Kong's Hang Seng Index jumping 2.43%, China's Shanghai Composite Index gaining 8.06% and India's BSE Sensex falling 1.49%.
Japan&#8217;s housing starts fell by 5.1% year-over-year in August compared to a 0.2% decline in the prior month, while industrial production fell by 3.3% month-over-month in August. Retail sales in Japan climbed by 2.8% year-over-year in August.
The official NBS Non-Manufacturing PMI in China fell to 50.0 in September from 50.3 in the prior month, while official NBS Manufacturing PMI climbed to 49.8 in September from 49.1 in August.
Economics
The Chicago PMI rose to 46.6 in September from 46.1 in August versus market estimates of 46.2.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41064318/top-3-real-estate-stocks-that-are-preparing-to-pump-this-month">Top 3 Real Estate Stocks That Are Preparing To Pump This Month</a></li>
</ul>

Earnings

Long Ideas

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Cantor Fitzgerald analyst Charles Duncan reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Prothena Corp

Oppenheimer analyst Jay Olson maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Outperform and lowers the price target from $66 to $62.

Oppenheimer Maintains Outperform on Prothena Corp, Lowers Price Target to $62

RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Sector Perform and lowers the price target from $28 to $24.

RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $24

WIIM

Prothena shares are trading higher after the company reported better-than-expected Q2 financial results.

Prothena Corp Q2 Collaboration Revenue $132.000M

RBC Capital analyst Brian Abrahams reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Sector Perform and maintains $28 price target.

RBC Capital Reiterates Sector Perform on Prothena Corp, Maintains $28 Price Target

Contracts

Prothena to Receive $80 Million from Bristol Myers Squibb for Exclusive Global License to PRX019; Phase 1 Clinical Trial to Begin in 2024

JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Market Outperform and lowers the price target from $85 to $83.

JMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $83

HC Wainwright &amp; Co. analyst Andrew Fein maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and lowers the price target from $90 to $84.

HC Wainwright & Co. Maintains Buy on Prothena Corp, Lowers Price Target to $84

Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.20) by 11.67 percent. The company reported quarterly sales of $900.00 thousand which missed the analyst consensus estimate of $2.17 million by 58.44 percent. This is a 58.51 percent decrease over sales of $2.17 million the same period last year.

Earnings Misses

Prothena Corp Q1 2024 GAAP EPS $(1.34) Misses $(1.20) Estimate, Sales $900.00K Miss $2.17M Estimate

Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential best-in-class anti-amyloid treatment for AL amyloidosis. The publication can be found in the latest issue of Leukemia &amp; Lymphoma, an international peer-reviewed journal that publishes research on all aspects of hematological malignancies.
AL amyloidosis is an idiopathic, rare, progressive and often fatal disease characterized by amyloid deposits that build up in vital organs leading to damage, dysfunction and failure. The risk of early mortality is especially high in patients with significant cardiac involvement as there are no current treatment options that target existing amyloid deposits in these patients.
Birtamimab binds to a highly conserved cryptic epitope which is only exposed in misfolded kappa and lambda light chain (LC) protein. Birtamimab binds and neutralizes soluble, toxic LC aggregates and binds and clears insoluble AL amyloid deposits, without affecting normally folded LC proteins. This mechanism of action is complementary to the current standard of care therapy for AL amyloidosis which does not target the existing toxic LC aggregates and amyloid deposits.
"Birtamimab was designed to clear deposited amyloid from vital organs and is the only treatment that has shown a significant survival benefit in patients with Mayo Stage IV AL amyloidosis, which was demonstrated in a post hoc analysis of the Phase 3 VITAL placebo-controlled clinical trial," said Hideki Garren, M.D., Ph.D., Chief Medical Officer, Prothena. "Birtamimab is being evaluated in patients with Mayo Stage IV AL amyloidosis, who are at high risk of early mortality, in the ongoing confirmatory Phase 3 AFFIRM-AL clinical trial."
A copy of the peer-reviewed article can be found here in Leukemia &amp; Lymphoma:

Biotech

General

Prothena Announces Review On Birtamimab Mechanism Of Action And Pharmacological Characteristics Published In Leukemia & Lymphoma

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $72.5, a high estimate of $129.00, and a low estimate of $35.00. Observing a downward trend, the current average is 6.88% lower than the prior average price target of $77.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1710338436_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Prothena Corp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$85.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$35.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$36.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$129.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Prothena Corp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Prothena Corp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Prothena Corp's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Prothena Corp</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>Prothena Corp: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Prothena Corp's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -99.37% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Prothena Corp's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -21353.16%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Prothena Corp's ROE stands out, surpassing industry averages. With an impressive ROE of -11.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Prothena Corp's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.35%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Prothena Corp's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Prothena Corp: Insights From 8 Analyst Reviews

Analyst Jason Butler from JMP Securities reiterated a Buy rating on Prothena (PRTA – Research Report) and keeping the price target at $83.00. Jason...

Prothena's Promising Pipeline and Strong Financials Merit a Buy Rating, with an $83 Price Target

Analyst Andrew Fein of H.C. Wainwright assigned a Buy rating on Prothena (PRTA – Research Report), with a price target of $84.00. Andrew Fein has g...

Analyst Endorses Prothena's Therapeutic Advances in Parkinson's and Alzheimer's Treatments

Piper Sandler analyst Yasmeen Rahimi assigned a Buy rating to Prothena (PRTA – Research Report) today and set a price target of $94.00. The company...

Prothena (PRTA) Gets a Buy from Piper Sandler

Which small-cap stocks look attractive currently? According to Wall Street analysts, the three stocks discussed below have earned a Strong Buy cons...

3 Small-Cap Stocks with Big Potential, Say Analysts (8/13/24)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Crinetics Pharmaceuticals (CRNX – Research Report), ...

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Prothena (PRTA) and Xenon (XENE)

Oppenheimer analyst Jay Olson maintained a Buy rating on Prothena (PRTA – Research Report) today and set a price target of $62.00. The company's sh...

Oppenheimer Remains a Buy on Prothena (PRTA)

The latest update is out from Prothena ( ($PRTA) ). Prothena Corporation has announced a strategic leadership change as Dr. Hideki Garren steps dow...

Prothena Leadership Transition Amid Neurodegenerative R&D Push

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Prothena (PRTA – Research Report), with a price target of $62.00....

Oppenheimer Keeps Their Buy Rating on Prothena (PRTA)

Prothena (PRTA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank ...

Maintaining Hold on Prothena Amid Executive Changes and Clinical Validation Needs

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Prothena (PRTA – Research Report). The associated price target remains t...

Prothena Buy Rating Affirmed: Leadership Changes and Prasinezumab's Promise Signal Investment Opportunity

CRNX

SANA

XENE

ZLAB

Press Releases

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena to Report First Quarter 2024 Financial Results on May 8

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Comments

Prothena Corp

Notizie

Ultime notizie per Prothena Corp (NASDAQ:PRTA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO